Cargando…

Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso

Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range o...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombini, Anaïs, Trotter, Caroline, Madrid, Yvette, Karachaliou, Andromachi, Preziosi, Marie-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639502/
https://www.ncbi.nlm.nih.gov/pubmed/26553677
http://dx.doi.org/10.1093/cid/civ600
_version_ 1782399924585889792
author Colombini, Anaïs
Trotter, Caroline
Madrid, Yvette
Karachaliou, Andromachi
Preziosi, Marie-Pierre
author_facet Colombini, Anaïs
Trotter, Caroline
Madrid, Yvette
Karachaliou, Andromachi
Preziosi, Marie-Pierre
author_sort Colombini, Anaïs
collection PubMed
description Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso. Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination campaign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature review, which included unpublished programmatic documents and peer-reviewed publications. The future disease burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria meningitidis. Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases. Most of the savings are accrued from lower costs of case management and household costs resulting from a lower burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves an additional 1.3 USD compared to the reactive strategy. Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system and for households, compared with the reactive strategy. This will protect households from catastrophic expenditures and increase the development capacity of the population.
format Online
Article
Text
id pubmed-4639502
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-46395022015-11-12 Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso Colombini, Anaïs Trotter, Caroline Madrid, Yvette Karachaliou, Andromachi Preziosi, Marie-Pierre Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso. Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination campaign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature review, which included unpublished programmatic documents and peer-reviewed publications. The future disease burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria meningitidis. Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases. Most of the savings are accrued from lower costs of case management and household costs resulting from a lower burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves an additional 1.3 USD compared to the reactive strategy. Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system and for households, compared with the reactive strategy. This will protect households from catastrophic expenditures and increase the development capacity of the population. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639502/ /pubmed/26553677 http://dx.doi.org/10.1093/cid/civ600 Text en © 2015 World Health Organization; licensee Oxford Journals. http://creativecommons.org/licenses/by/3.0/igo/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL
spellingShingle The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Colombini, Anaïs
Trotter, Caroline
Madrid, Yvette
Karachaliou, Andromachi
Preziosi, Marie-Pierre
Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title_full Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title_fullStr Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title_full_unstemmed Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title_short Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
title_sort costs of neisseria meningitidis group a disease and economic impact of vaccination in burkina faso
topic The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639502/
https://www.ncbi.nlm.nih.gov/pubmed/26553677
http://dx.doi.org/10.1093/cid/civ600
work_keys_str_mv AT colombinianais costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso
AT trottercaroline costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso
AT madridyvette costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso
AT karachaliouandromachi costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso
AT preziosimariepierre costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso